摘要
目的观察厄洛替尼单药治疗化疗失败的晚期肺腺癌的疗效及毒副反应。方法 21例晚期肺腺癌口服厄洛替尼,连服2个月后评价近期疗效及毒副反应。结果 21例中PR 5例,SD 10例,PD 6例,有效率为23.80%;疾病控制率为71.43%;中位肿瘤进展为5.6个月;中位生存期为11.7个月。主要的毒副反应为皮疹、皮肤瘙痒、腹泻、恶心,多为Ⅰ-Ⅱ度,对症处理后可缓解。结论厄洛替尼单药治疗化疗失败的晚期肺腺癌患者疗效好,能延长其生存时间和提高生活质量,且毒副反应轻。
Objective To evaluate the efficacy and the side effect of erlotinib in previously treated patients with lung adenocarcinoma. Methods Twenty-one patients with advanced lung adenocarcinoma were treated with erlotinib which was given orally as a single dose of 150 mg per day. The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria. Results There was no CR,PR 5 cases,SD 10 eases,PD 6 cases,the response rate was 23.80% ,the disease control rate was 71.43%. The median time to progression was 5.6 months, the median survival time was 11.7 months. The main toxicities were rash and itch of skin, diarrhea and nausea, which could be relieved by treatment. Conclusion It is effective and feasible to treat patients with advanced lung adenocarcinoma by means of erlotinib as the second-line therapy.
出处
《肿瘤基础与临床》
2010年第3期218-220,共3页
journal of basic and clinical oncology
关键词
肺腺癌
厄洛替尼
靶向治疗
lung adenoearcinoma
erlotinib
target therapy
